翔宇医疗1月13日晚间发布的一则股东拟减持公告备受市场关注。针对此次减持，翔宇医疗董事会办公 室相关人士回应称，公司内部股东近5年未进行减持，期间还多次实施股份回购，且董事长曾增持股 份，本次减持属于正常资金安排，有利于优化股东结构。该人士同时透露，公司脑机接口相关产业链延 伸布局已启动，上市公司体系外拟开办脑机接口临床应用为特色的康复医院，目前已取得实质性进展， 此项业务有望成为上市公司新增长曲线。至于其他规划，公司暂未透露更多信息。（中证金牛座） ...

公告显示，安阳启旭、河南翔宇健康产业管理有限公司同受公司实际控制人何永正、郭军玲夫妇控 制。 翔宇医疗于2021年3月31日在上交所科创板上市，发行数量为40,000,000股（全部为新股，不安排老 股转让），发行价格为28.82元/股，保荐机构为海通证券股份有限公司（现更名为国泰海通证券股份有 限公司），保荐代表人为刘君、岑平一。 翔宇医疗首次公开发行募集资金总额115,280.00万元；扣除发行费用后，募集资金净额为104,965.66 万元。翔宇医疗最终募集资金净额较原计划多34,165.66万元。翔宇医疗于2021年3月25日发布的招股说 明书显示，公司拟募集资金70,800.00万元，智能康复医疗设备生产技术改造项目、养老及产后康复医疗 设备生产建设项目、康复设备研发及展览中心建设项目、智能康复设备（西南）研销中心项目、运营储 备资金。 翔宇医疗发行费用总额10,314.34万元，其中保荐及承销费用7,939.04万元。 中国经济网北京1月14日讯 翔宇医疗(688626.SH)昨日晚间披露关于股东减持股份计划公告。 公司股东安阳启旭贸易咨询服务中心（有限合伙）（简称"安阳启旭"）持有公司股份 8, ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 1.00% as of January 14, 2026, with Tianzhihang leading the gain at 18.97% and Rongchang Biopharmaceuticals experiencing the largest drop at 9.83% [1] - Eight departments jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," emphasizing the promotion of intelligent equipment iteration and supporting AI applications in high-end medical equipment and telemedicine [1] - Nvidia and Eli Lilly announced the establishment of an AI joint laboratory, planning to invest up to $1 billion over the next five years to accelerate drug development, indicating increased investment from leading overseas companies in domestic related fields [1] Group 2 - CITIC Securities reported that the medical AI sector is expected to accelerate the restructuring of the trillion-yuan pharmaceutical market, with a fundamental change in the payment logic for AI medical services anticipated in 2026 [2] - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 48.85% as of December 31, 2025, including companies like United Imaging Healthcare and BeiGene [2] Group 3 - The Jiashi Sci-Tech Medical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, providing an opportunity for investors to easily access the biopharmaceutical sector [3]

格隆汇1月14日｜翔宇医疗(688626.SH)今日早盘一度跌7.66%至80.1元。翔宇医疗公告称，股东安阳启旭贸易咨询服务中心(有限合伙)计划减持不超过480万 股，占公司总股本的3%，减持方式为集中竞价和大宗交易。减持原因为自身资金需求，减持期间为2026年2月4日至2026年5月3日。(格隆汇) ...

科创板个股中，截至发稿上涨的共有482只，涨幅在10%以上的共有9只，涨幅较高的有光云科技、中钢 洛耐、佰维存储等，分别上涨20.00%、17.83%、12.66%，下跌的有106只，跌幅较大的有翔宇医疗、悦 康药业、呈和科技，分别下跌4.44%、4.10%、3.88%。 资金面上，光云科技上一交易日主力资金净流入3946.46万元，近5日净流入1.93亿元。 融资融券数据显示，该股最新（1月13日）两融余额为3.30亿元，其中，融资余额为3.30亿元，较上一个 交易日增加7575.54万元，增幅为29.85%；融券余额为44.46万元，较上一个交易日增加18.27万元，增幅 为69.74%。近10日两融余额合计增加1.24亿元，增幅为59.91%，其间融资余额增长59.78%，融券余额增 长336.22%。（数据宝） （文章来源：证券时报网） 1月14日盘中科创板股光云科技涨停，截至09:40，股价报34.20元，成交6.05亿元，换手率4.35%，振幅 13.65%。 ...

Market Dynamics - International oil prices reached their highest level since October last year, with WTI crude oil futures closing at $61.15 per barrel, up 2.77%, and Brent crude at $65.47 per barrel, up 2.51% [1] - The U.S. stock market saw all three major indices decline, with the Nasdaq China Golden Dragon Index dropping 1.86%. Intel shares rose over 7%, reaching a nearly two-year high [1] - The U.S. December core CPI increased by 2.6% year-on-year, below expectations, while the overall CPI rose by 2.7%, aligning with market forecasts [1] Commodity Trends - Spot silver prices hit $89 per ounce, rising 4.65% and marking a historical high, with significant intraday gains [2] - Lithium carbonate futures reached a two-year high, peaking at 174,060 yuan per ton, driven by increased demand and supply concerns [2][4] Corporate Developments - NVIDIA received approval from the U.S. government to ease export restrictions on its H200 chips to China, with the U.S. Department of Commerce overseeing the sales [2] - Rongbai Technology signed an agreement with CATL to supply 3.05 million tons of lithium iron phosphate cathode materials, with total sales exceeding 120 billion yuan [2][4] - Guizhou Moutai announced a shift in its sales model to a multi-channel approach, aiming for a dynamic pricing mechanism [4] Industry Insights - The AI-driven pharmaceutical market in China is projected to grow significantly, with a compound annual growth rate of 47.8% from 2019 to 2024, and expected to reach 58.6 billion yuan by 2028 [7] - The industrial internet sector in China is set to expand, with the Ministry of Industry and Information Technology reporting over 8,000 5G factories and a projected core industry scale exceeding 1.6 trillion yuan by 2025 [9] Investment Opportunities - The storage industry is entering a "super cycle," with a projected net profit increase of 1225.40% to 1449.67% for a leading company in Q4 2025 [5] - The AI-driven storage chip market is expected to see significant price increases due to supply-demand mismatches [5]

Market News - US stock indices collectively declined, with the Dow Jones down 0.8%, Nasdaq down 0.1%, and S&P 500 down 0.19% [1] - Bank stocks fell broadly, with the KBW Bank Index down 1.3% and JPMorgan down 4.2% [1] - International oil prices rose significantly, with WTI crude up 2.61% at $61.05 per barrel and Brent crude up 2.44% at $65.43 per barrel [1] - International gold prices decreased, with spot gold down 0.26% at $4585.37 per ounce [1] - The Nasdaq Golden Dragon China Index fell 1.86%, with Pinduoduo down over 5% and NIO and Xpeng down over 3% [1] Industry Insights - The Sichuan Province's "14th Five-Year" basic surveying and mapping plan aims to enhance the Beidou satellite navigation system, improving service coverage and precision [3] - The Ministry of Industry and Information Technology released an action plan for the high-quality development of industrial internet platforms, targeting over 450 influential platforms by 2028 and a device connection number exceeding 1.2 million [4] - Jiangsu Province's "Artificial Intelligence +" action plan focuses on enhancing biopharmaceutical R&D capabilities and promoting AI applications in drug discovery and medical device manufacturing [6] Stock Movements - Jixin Technology announced a plan for a shareholder to reduce holdings by up to 969.03 million shares, representing 1% of total shares [7] - Zhang Yijie, a shareholder of Zhangyue Technology, plans to reduce holdings by up to 438.9 million shares, also 1% of total shares [7] - The controlling shareholder of Zhejiang Yongqiang plans to reduce holdings by up to 24.4 million shares, accounting for 1.13% of total shares [7]

Mergers and Acquisitions - Lianjian Technology plans to acquire 55% equity of Zhongding Testing for 101 million yuan, making it a subsidiary included in the consolidated financial statements after the transaction [1] Termination of Asset Purchase - Yaxing Chemical announced the termination of its plan to issue shares and pay cash for the acquisition of 100% equity of Shandong Tianyi Chemical, which was expected to constitute a major asset restructuring [2] Earnings Disclosure - Kanglong Chemical expects a net profit of 1.614 billion to 1.686 billion yuan for 2025, a year-on-year decrease of 6% to 10%, while revenue is projected to grow by 13% to 16% [3] - Yongyou Network anticipates a net loss of 1.3 billion to 1.39 billion yuan for 2025, reducing losses by 671 million to 761 million yuan year-on-year [4] - Dongpeng Beverage expects a net profit of 4.34 billion to 4.59 billion yuan for 2025, an increase of 1.013 billion to 1.263 billion yuan, representing a growth of 30.46% to 37.97% [5] - Pudong Development Bank forecasts a net profit of 50.017 billion yuan for 2025, a year-on-year increase of 10.52%, with revenue expected to be 173.964 billion yuan, up 1.88% [6] Shareholding Changes - Zhang Yijie, a shareholder of Jixin Technology, plans to reduce holdings by up to 969,030 shares, not exceeding 1% of the total share capital, for personal financial needs [8] - Quantum Leap, a shareholder of Zhangyue Technology, intends to reduce its stake by up to 438,900 shares, not exceeding 1% of the total share capital, due to personal needs [7] - Alibaba Health, a major shareholder of Shuyupingmin, plans to reduce its holdings by up to 810,720 shares, accounting for 2% of the total share capital, for personal financial needs [9] - Anyang Qixu, a shareholder of Xiangyu Medical, intends to reduce its stake by up to 480,000 shares, not exceeding 3% of the total share capital, due to personal financial needs [10] Risk Matters - *ST Lifang announced that its stock price has fallen below 1 yuan, which may lead to delisting due to the stock price being below par value, and it has received a notice of administrative penalty for false records in annual reports from 2021 to 2023 [11]

Group 1 - Hongsheng Co., Ltd. has not generated revenue in the data center liquid cooling sector [1] - Oriental Pearl does not directly engage in AI business, and AI applications do not directly generate revenue [1] - Tongda Hai's AI-driven revenue accounts for a low proportion of the company's overall operating income [1] Group 2 - Beibu Gulf Port plans to invest 11.403 billion yuan in the construction of a 300,000-ton terminal project in Fangchenggang [1] - Beibu Gulf Port also plans to invest in the construction of the Beibu Gulf Port Beihai Port area Tiezhong Port District No. 4 and No. 5 berth project [1] - LeKai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film coating production line project [1] Group 3 - Aopt plans to undertake a 120 million yuan 2D vision solution project for Goer [1] - Wantong Expressway has won a project worth 7.237 billion yuan [1] - Pingzhi Information is expected to win a project worth 37.5884 million yuan [1] Group 4 - Aidi Pharmaceutical intends to acquire a 22.2324% stake in Nanda Pharmaceutical for 130 million yuan [1] - Kaifa Electric plans to repurchase shares worth 30 million to 60 million yuan [1] - Haojiang Intelligent plans to repurchase shares worth 1.5 million to 3 million yuan [1] Group 5 - Huazhi Jie plans to spend 30 million to 50 million yuan on share repurchase [2] - New Work Group intends to reduce its stake in China New Group by no more than 3% [2] - Zhejiang Yongqiang's shareholder plans to reduce its stake by no more than 1.13% [2] Group 6 - Shandong Pharmaceutical Glass plans to raise no more than 3.235 billion yuan through a private placement [2] - Fulin Precision plans to raise 3.175 billion yuan through a private placement to Ningde Times [2] - Yuanwang Valley plans to raise no more than 690 million yuan through a private placement [2]

Group 1: Share Buybacks and Increases - Prolo Pharmaceutical's controlling shareholder plans to increase its stake by 60 million to 120 million yuan [3] - BAIC Blue Valley and some directors and executives plan to increase their holdings by 14.5 million to 16.4 million yuan [3] - Zhongju High-tech has obtained a commitment letter for a stock repurchase loan of 540 million yuan from a financial institution [3] - Haojiang Intelligent plans to use its own funds to repurchase shares for equity incentives or employee stock ownership plans [3] - Huazhi Jie intends to repurchase shares worth 30 million to 50 million yuan [3] - Nanshan Aluminum plans to repurchase shares worth 300 million to 600 million yuan for cancellation [3] Group 2: Share Reductions - New Work Group, a shareholder of Zhongxin Group, plans to reduce its stake by no more than 3% [3] - Hongqi Technology's shareholders plan to reduce their holdings by no more than 4.68% [3] - Zhejiang Yongqiang's shareholder, Xie Jianqiang, plans to reduce his stake by no more than 1.13% [3] - Xiangyu Medical's shareholder, Anyang Qixu, plans to reduce his stake by no more than 3% [3] - Shuyuan Pingmin's shareholder, Ali Health, plans to reduce his stake by no more than 2% [3] - Hongqiang Co., Ltd.'s actual controller plans to reduce no more than 2.1161 million shares, not exceeding 1% of the total share capital [3] - China Merchants Shipping's directors and executives plan to collectively reduce their holdings by no more than 648,600 shares [3] - Zhang Yijie, a shareholder of Jixin Technology, plans to reduce his stake by no more than 1% [3] - Dingjie Smart's major shareholder, Industrial Fulian, reduced its stake by 1.14% from January 9 to January 12 [3] - Zhongli Co., Ltd.'s shareholders plan to reduce their holdings by no more than 0.75% [3]